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S.S. Lee ∗, D.K.P. Tam
Stanley Ho Centre for Emerging Infectious Diseases, Chinese
University of Hong Kong, Hong Kong, China
Background: In the health care setting, vaccination of
health care workers serves the key purpose of preventing
the occurrence of nosocomial infection. Acceptance of vac-
cination is therefore an important determinant of effective
infection control.Methods: A self-administered question-
naire survey was conducted in 2007 on nurses in Hong Kong.
Participants were asked to indicate their status on inﬂuenza
vaccination in the preceding season, their intention to be
vaccinated in the following year, and hepatitis B vaccination.
Reasons for and against their vaccination were collected.
Results: A total of 781 nurses completed the question-
naires. About half (48.8%) were aged between 36 and 45;
female to male ratio 6:1; and 54.0% had been in nursing
practice for at least 10 years. Above 80% were at fre-
quent or regular contact with patients in the course of
their work. After exclusion of hepatitis B carriers, 90.0%
had received hepatitis B vaccination before or after join-
ing the nursing profession. Overall, 44.3% had received
inﬂuenza vaccination in the preceding season. Of those
eligible for both vaccines, rejection of inﬂuenza vaccina-
tion was associated with long working experience (48.2%
vs 58.3%, OR = 0.67; 95% CI 0.48, 0.93), frequent contact
with patients (56.5% vs 43.9%, OR = 1.67; 95% CI 1.14, 2.38),
perceived ineffectiveness of vaccination (81.5% vs 31.5%,
OR = 7.58; 95% CI 6.46, 14.20) and rejection of hepati-
tis B vaccination (70.7% vs 50.8%, OR = 2.34; 95% CI 1.30,
4.22)
Discussion: The low uptake of inﬂuenza vaccination in
health care workers was associated with a multitude of fac-
tors ranging from perceived ineffectiveness of vaccine, work
nature, as well as attitude towards other vaccines. Infection
control strategies may need to be tailored to the unique
health care setting to achieve better coverage of inﬂuenza
vaccination.
doi:10.1016/j.ijid.2008.05.356
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Post-Marketing Surveillance of the Adverse Events Fol-
lowing Immunization with a New Pentavalent Vaccine
(DPT-HB+Hib)
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Background: Combination vaccines are an important
trend in the development of vaccines to reduce the num-
ber of injections and to increase vaccination’s coverage. In
Cuba a new pentavalent vaccine was recently obtained in a
formulation where the DPT-HB component is mixed with the
monovalent Hib vaccine, just immediately before its admin-
istration. This vaccine was introduced into the National
Immunization Program (NIP) since September of 2006.
Objective: Evaluation of the adverse events following
immunization (AEFI) with the pentavalent vaccine admin-
istered under routine use through the NIP.
Methods: It was planned to include 3000-4000 children,
receiving any dose of this vaccine in 42 health areas repre-
senting the whole country. The study was carried out from
September to December 2006. Nurses were trained to fol-
low up all the AEFI occurring in the 72 hours after vaccination
(even causally related or not) and to ﬁll a form containing
all this information, with a scale of classiﬁcation of the most
probably found events. Data bases were designed, ﬁlled by
duplicated, and compared to discard mistakes, before the
analyses.
Results: A total of 4059 children were included, 47.5%
presented some event during the observation period. The
99.6% of events correspond to those asked in the inves-
tigation form. The most frequently adverse events were
fever 44.2%, slight fever 15.7%, irritability 11.6% and pain,
induration and erythema at the injection 14.9%, 5.5% and
5.1%, respectively. Those events represented the 97% out of
the total. Local events represent the 25%. According to the
severity AEFI were classiﬁed as mild (88%), moderate (11.9%)
and severe (0.1%). No death or sequels were reported.
Conclusions: The new pentavalent vaccine is safe and
well tolerated in infants <1 year. The AEFI and commonly
reported events showed no differences respect previous
clinical trials for product registration and vaccines of this
kind
doi:10.1016/j.ijid.2008.05.357
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Background: Priming against strains with pandemic
potential, such as H5N1, with vaccines that induce immuno-
logical memory and cross-reactivity, may form the ﬁrst line
of defence against a pandemic ﬂu. Safe and effective H5N1
vaccines, particularly those that can induce cross-reactive
immunity, are urgently needed for prepandemic vaccination
strategies.
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Methods: Healthy adults aged 18—60 years (n = 313) and
elderly aged >60 years (n = 173) received two injections
(1:1 ratio), 3 weeks apart, and a six-month booster dose,
of a subunit MF59-adjuvanted H5N1 (A/Vietnam/1194/2004)
inﬂuenza (clade 1) vaccine containing either 7.5g or 15g
hemagglutinin. All participants were followed for safety
assessments. Blood samples were taken before each vac-
cination, and again three weeks and six months after each
vaccination. Serum H5N1 antibody titres were assessed by
single radial hemolysis and microneutralisation assays.
Findings: Mild pain at the injection site was the most
common reaction overall and decreased with subsequent
dosing. The humoral immune response to 7.5g vaccine was
non-inferior to that of 15g. Seroprotection rates after the
second vaccination ranged from 80% to 86% as measured
by SRH and 76% to 85% as measured by MN assays across
vaccine dose and age strata. After the six-month booster,
seroprotection rates, as measured by SRH, increased in
adults and elderly in the 7.5g group from 19% and 22%
at baseline (pre-booster) to 90% and 84%, respectively,
three weeks later, and in the 15g group from 25% and
64% at baseline for adults and elderly, respectively, to
91% and 88%. Heterologous immune response against the
A/H5N1/turkey/Turkey/05 strain was detectable after the
second vaccination and the booster vaccination, with sero-
protection rate of 57—76% and 78—88% after the second and
third dose respectively.
Interpretations: Both formulations were well tolerated
and equivalent. The 7.5g met all three SRH criteria for
pandemic vaccines licensure in the EU in both adult and
elderly participants. The cross-clade immune response sug-
gests that this vaccine adjuvanted with MF 59 is appropriate
for H5N1 prepandemic vaccination programs.
doi:10.1016/j.ijid.2008.05.358
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Varicella Vaccine Effectiveness During An Outbreak in a
Partially Vaccinated Population, Sydney, Australia
B. Forssman ∗, T. Mannes, L. Gupta
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Background: Universal varicella vaccination was intro-
duced as a public health initiative in Australia in November
2005, but there are no reported vaccine effectiveness stud-
ies in Australia carried out since commencement of this
programme. An outbreak of varicella infection occurred in
a childcare centre (CCC) in Sydney, Australia in Septem-
ber 2006. We used this outbreak to assess varicella vaccine
effectiveness.
Methods: Self-administered questionnaires were used to
obtain vaccination status and medical history from parents
of all children at the CCC. The parents of all children with
varicella infection were then contacted by telephone to
obtain information regarding disease severity. Children aged
<12 months or who had varicella infection prior to the out-
break were excluded. Vaccine effectiveness was calculated
using the cohort method.
Results: 112 children attended the CCC at the time of
the outbreak; 86 questionnaires were returned (response
rate 77%). Ten children were excluded from the study due to
age or previous varicella infection. 54% (41/76) of suscepti-
ble children were vaccinated at the time of the outbreak.
There were 23 cases of varicella infection (attack rate 30%);
of these, 8 (35%) had previously received the varicella vac-
cine. All cases hadmild-moderate disease. The attack rate in
the vaccinated population was 20% (8/41) compared to 43%
(15/35) in the unvaccinated population. Vaccine efﬁcacy in
this outbreak was 54%. The relative risk (RR) of mild disease
in the unvaccinated compared to the vaccinated population
was 0.94, whereas the RR of moderate to severe disease was
11.7.
Conclusion: In this outbreak, varicella vaccine did not
appear to be effective in preventing an outbreak; however
it did have a likely impact on disease severity, appar-
ently effective in preventing moderate to severe disease.
Vaccination of vulnerable populations, including catch-
up of previously missed individuals, should be strongly
encouraged to reduce severity of disease during future out-
breaks.
doi:10.1016/j.ijid.2008.05.359
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Background: Dengue disease is a major public health
problem in tropical and subtropical areas. As any of the
four serotypes of dengue virus can cause the classic or
severe hemorrhagic forms of the disease, a tetravalent
dengue vaccine is needed. Prior exposure to a ﬂavivirus
could potentially modulate the safety and immunogenicity
of a tetravalent dengue vaccine.
Methods: This open, monocenter study in Australia inves-
tigated the effect of prior exposure to live-attenuated
ﬂavivirus vaccines on the safety, viremia and immunogenic-
ity of a recombinant, live attenuated tetravalent dengue
vaccine (TDV). TDV was given to subjects who were either:
ﬂavivirus na¨ıve, or had been randomized and vaccinated 1
year previously with yellow fever vaccine (YFV) or one of
two monovalent (serotype 1 or 2) live attenuated dengue
vaccines (MDV). Exposure to MDV was hypothesized to mim-
ick natural exposure. Adverse events, biological safety, and
dengue vaccine virus viremia (qRT-PCR) were assessed to
Day28. Neutralizing antibody levels against parental viruses
were assessed on D0 and 28 by PRNT50 assay. Subjects were
healthy adults aged 18—40.
Results: 35 subjects were enrolled and received TDV: 12
were ﬂavivus-na¨ıve, 8 had received YFV, 15 had received
MDV. Clinical or biological adverse reactions after TDV were
not more frequent or more severe among those previously
vaccinated with MDV or YFV, than among na¨ıve subjects. Vac-
cine virus viremia, predominantly serotype 4, was detected
on day 14 or 21 in 47% of MDV subjects, versus 88% of YF
subjects and 83% of na¨ıve subjects. After TDV vaccination,
